The trial achieved both its Most important endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and superior improvements in liver fibrosis without any worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH when compared with placebo.1These highlights never… Read More